Cardio Diagnostics Holdings, Inc. (CDIO) Stock

Cardio Diagnostics Holdings, Inc. (CDIO) is a Healthcare stock trading at $2.03 (as of 2026-06-18), with a market capitalization of $4.38M and a trailing P/E of -0.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. Its Epi+Gen CHD test is designed to assess the risk of symptomatic coronary heart disease over a three-year period.

Valuation — source: SEC EDGAR (first-party)
Price$2.03
Market Cap$4.38M
P/E Ratio-0.6
EV / EBITDA0.2
Price / Book0.65
Price / Sales350.17
DCF Value (model)$-32.29
DCF Upside vs Price-1690.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$14825.00
Net Margin-43832.5%
Return on Equity-74.7%
Current Ratio15.76
Revenue Growth (YoY)-57.5%
EPS Growth (YoY)1096.8%
FCF Growth (YoY)13.6%
Financial Health — source: SEC EDGAR
Altman Z-Score-2.66 (distress)
Valuation vs Sector & Industry
Stock P/E-0.6
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-102.8%
vs Industry-103.4%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJANE STREET GROUP, LLC ($158502.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMeeshanthini V. Dogan
Employees13
CountryUS
IPO Date2022-01-14

Related Companies (Business model: Clinical Labs / CRO Services; 8 closest by market cap; US-domiciled)

  • Q/C Technologies, Inc. (QCLS)
  • Advanced Biomed Inc. Common Stock (ADVB)
  • American Shared Hospital Services (AMS)
  • BioNexus Gene Lab Corp. (BGLC)
  • Biomerica, Inc. (BMRA)
  • bioAffinity Technologies, Inc. (BIAF)
  • Aclarion, Inc. (ACON)
  • iSpecimen Inc. (ISPC)
CDIO earnings history · CDIO institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.